Dr. Sunil Verma on the Evolution of Treatment in HER2-Positive Breast Cancer
Verma says one of the major new understandings of the disease is that the HER2 receptor needs to be suppressed at all times within the treatment paradigm of the malignancy.
Sunil Verma, MD, Medical Director, Tom Baker Cancer Centre, Professor and Department Head, Oncology, Cumming School of Medicine, University of Calgary, discusses the advances in HER2-positive breast cancer in recent years. Verma says one of the major new understandings of the disease is that the HER2 receptor needs to be suppressed at all times within the treatment paradigm of the malignancy. He adds that another big advance within the malignancy is the inclusion of pertuzimab in treatment sequencing, which has improved progression free and overall survival for these patients.
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
